501 related articles for article (PubMed ID: 27324636)
1. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
Prenner SB; Shah SJ; Yancy CW
Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/Valsartan (LCZ696) in Heart Failure.
Khder Y; Shi V; McMurray JJV; Lefkowitz MP
Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
Gori M; Senni M
Expert Rev Cardiovasc Ther; 2016; 14(2):145-53. PubMed ID: 26642078
[TBL] [Abstract][Full Text] [Related]
4. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Lillyblad MP
Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
[TBL] [Abstract][Full Text] [Related]
5. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.
Docherty KF; McMurray JJV
Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240
[TBL] [Abstract][Full Text] [Related]
7. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Macdonald PS
Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
[TBL] [Abstract][Full Text] [Related]
8. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
[TBL] [Abstract][Full Text] [Related]
9. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
McMurray JJ
Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
[TBL] [Abstract][Full Text] [Related]
10. LCZ696 : a new paradigm for the treatment of heart failure?
Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P
Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387
[TBL] [Abstract][Full Text] [Related]
11. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
12. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Ansara AJ; Kolanczyk DM; Koehler JM
J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Vaduganathan M; Desai AS
Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
[TBL] [Abstract][Full Text] [Related]
14. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
[TBL] [Abstract][Full Text] [Related]
15. The Role of Neprilysin Inhibitors in Cardiovascular Disease.
Mills J; Vardeny O
Curr Heart Fail Rep; 2015 Dec; 12(6):389-94. PubMed ID: 26466607
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Kompa AR; Lu J; Weller TJ; Kelly DJ; Krum H; von Lueder TG; Wang BH
Int J Cardiol; 2018 May; 258():192-198. PubMed ID: 29544929
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
Nochioka K; Sakata Y; Shimokawa H
Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
[TBL] [Abstract][Full Text] [Related]
18. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
Andersen MB; Simonsen U; Wehland M; Pietsch J; Grimm D
Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):14-22. PubMed ID: 26280447
[TBL] [Abstract][Full Text] [Related]
19. Limitations of Sacubitril/Valsartan in the Management of Heart Failure.
Yandrapalli S; Aronow WS; Mondal P; Chabbott DR
Am J Ther; 2017; 24(2):e234-e239. PubMed ID: 27574931
[TBL] [Abstract][Full Text] [Related]
20. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Vardeny O; Miller R; Solomon SD
JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
